Results

1–10 of 154 results for Age-Related Macular Degeneration

Impact of Vitrectomy Surgery on the Progression of Age-Related Macular Degeneration
Annual Meeting Talks
2024
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2024
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024
Delayed Near Infrared Analysis Identifies Novel Features of Nonexudative Dry Age-Related Macular Degeneration in a Natural History Study: Baseline Findings
Shelley Boyd, MD, FRCS(C)
Annual Meeting Talks
2024
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults With Neovascular Age-related Macular Degeneration
Raj K. Maturi, MD
Annual Meeting Talks
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2024
Association Between Age-Related Macular Degeneration and Diabetic Retinopathy in Type 2 Diabetes Mellitus: A Retrospective Study Using the Vestrum Health Database
Daniel A. Adelberg, MD, FASRS
Annual Meeting Talks
2024
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025